Advertisement
Singapore markets open in 7 hours 11 minutes
  • Straits Times Index

    3,367.90
    +29.33 (+0.88%)
     
  • S&P 500

    5,489.96
    +14.87 (+0.27%)
     
  • Dow

    39,192.13
    +22.61 (+0.06%)
     
  • Nasdaq

    17,976.70
    +97.40 (+0.54%)
     
  • Bitcoin USD

    61,977.41
    -1,516.56 (-2.39%)
     
  • CMC Crypto 200

    1,308.86
    -35.64 (-2.65%)
     
  • FTSE 100

    8,121.20
    -45.56 (-0.56%)
     
  • Gold

    2,332.70
    -6.20 (-0.27%)
     
  • Crude Oil

    83.26
    -0.12 (-0.14%)
     
  • 10-Yr Bond

    4.4530
    -0.0260 (-0.58%)
     
  • Nikkei

    40,074.69
    +443.63 (+1.12%)
     
  • Hang Seng

    17,769.14
    +50.53 (+0.29%)
     
  • FTSE Bursa Malaysia

    1,597.96
    -0.24 (-0.02%)
     
  • Jakarta Composite Index

    7,125.14
    -14.48 (-0.20%)
     
  • PSE Index

    6,358.96
    -39.81 (-0.62%)
     

Tarsus Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations

Tarsus Pharmaceuticals (NASDAQ:TARS) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$27.6m (up by US$25.1m from 1Q 2023).

  • Net loss: US$35.7m (loss widened by 53% from 1Q 2023).

  • US$1.01 loss per share (further deteriorated from US$0.88 loss in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Tarsus Pharmaceuticals Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 43%. Earnings per share (EPS) also surpassed analyst estimates by 15%.

Looking ahead, revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Pharmaceuticals industry in the US.

ADVERTISEMENT

Performance of the American Pharmaceuticals industry.

The company's shares are down 7.6% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Tarsus Pharmaceuticals, and understanding it should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.